The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase Ia/Ib dose-escalation study of IBI110 (anti-LAG-3 mAb) as a single agent and in combination with sintilimab (anti-PD-1 mAb) in patients (pts) with advanced solid tumors.
 
Cai Zhou
No Relationships to Disclose
 
Yayi He
No Relationships to Disclose
 
Shengxiang Ren
No Relationships to Disclose
 
Wei Li
No Relationships to Disclose
 
Jun Zhu
No Relationships to Disclose
 
Jia Yu
No Relationships to Disclose
 
Lei Wang
No Relationships to Disclose
 
Anwen Xiong
No Relationships to Disclose
 
Nong Xu
No Relationships to Disclose
 
Chenyu Mao
No Relationships to Disclose
 
Beiqing Pan
Employment - Innovent Biologics
 
Ying Liu
Employment - Innovent Biologics
 
Hui Zhou
Employment - Innovent Biologics